Morikazu Miyamoto1, Hitoshi Tsuda2, Atsushi Sugiura3, Tsunekazu Kita3, Yoshitaka Kataoka4, Kenji Ishii4, Kazuya Kudo5, Hiroko Matsuura6, Hiroki Ishibashi6, Hideki Iwahashi6, Taira Hada6, Rie Suzuki6, Masashi Takano6. 1. Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Saitama, Japan; mmiyamoto@ndmc.ac.jp. 2. Department of Basic Pathology, National Defense Medical College Hospital, Saitama, Japan. 3. Department of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Nara, Japan. 4. Department of Gynecology, Nishisaitama-chuo National Hospital, Saitama, Japan. 5. Department of Gynecology, Tama-Hokubu Medical Center, Tokyo, Japan. 6. Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Saitama, Japan.
Abstract
BACKGROUND/AIM: In 2020, the percentages were removed from the World Health Organization's criteria for mixed carcinoma. The aim was to examine the clinical significance of an area of serous carcinoma (SC) <5%. PATIENTS AND METHODS: Our study included 236 patients with the 2009 International Federation of Obstetrics and Gynecology (FIGO) stage IA grade 1 endometrioid carcinoma (EG1) from multiple hospitals. EG1 patients with an area of SC <5% and those with pure-type EG1 were retrospectively compared. RESULTS: In the multivariate analysis for recurrence, an area of SC <5% was an independent risk factor [hazard ratio (HR)=101.51, p<0.01]. In the multivariate analysis for progression-free survival, an area of SC <5% was identified as a negative prognostic factor (HR=62.43, p<0.01). CONCLUSION: EG1 with an area of SC <5% may be more aggressive than pure-type EG1 at FIGO stage IA. Copyright
BACKGROUND/AIM: In 2020, the percentages were removed from the World Health Organization's criteria for mixed carcinoma. The aim was to examine the clinical significance of an area of serous carcinoma (SC) <5%. PATIENTS AND METHODS: Our study included 236 patients with the 2009 International Federation of Obstetrics and Gynecology (FIGO) stage IA grade 1 endometrioid carcinoma (EG1) from multiple hospitals. EG1patients with an area of SC <5% and those with pure-type EG1 were retrospectively compared. RESULTS: In the multivariate analysis for recurrence, an area of SC <5% was an independent risk factor [hazard ratio (HR)=101.51, p<0.01]. In the multivariate analysis for progression-free survival, an area of SC <5% was identified as a negative prognostic factor (HR=62.43, p<0.01). CONCLUSION:EG1 with an area of SC <5% may be more aggressive than pure-type EG1 at FIGO stage IA. Copyright
Authors: C L Creutzberg; W L van Putten; P C Koper; M L Lybeert; J J Jobsen; C C Wárlám-Rodenhuis; K A De Winter; L C Lutgens; A C van den Bergh; E van de Steen-Banasik; H Beerman; M van Lent Journal: Lancet Date: 2000-04-22 Impact factor: 79.321
Authors: Sharyn N Lewin; Thomas J Herzog; Nicanor I Barrena Medel; Israel Deutsch; William M Burke; Xuming Sun; Jason D Wright Journal: Obstet Gynecol Date: 2010-11 Impact factor: 7.661
Authors: Amanda Nickles Fader; David Starks; Paola A Gehrig; Angeles Alvarez Secord; Heidi E Frasure; David M O'Malley; Erin R Tuller; Peter G Rose; Laura J Havrilesky; Kathleen N Moore; Warner K Huh; Allison E Axtell; Joseph L Kelley; Kristine M Zanotti Journal: Gynecol Oncol Date: 2009-08-26 Impact factor: 5.482
Authors: Brian M Slomovitz; Thomas W Burke; Patricia J Eifel; Lois M Ramondetta; Elvio G Silva; Anuja Jhingran; Jonathan C Oh; E Neely Atkinson; Russell R Broaddus; David M Gershenson; Karen H Lu Journal: Gynecol Oncol Date: 2003-12 Impact factor: 5.482
Authors: Andres G Chiesa-Vottero; Anais Malpica; Michael T Deavers; Russell Broaddus; Gerard J Nuovo; Elvio G Silva Journal: Int J Gynecol Pathol Date: 2007-07 Impact factor: 2.762
Authors: Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan Journal: Br J Cancer Date: 2006-03-13 Impact factor: 7.640